|
Apr 18
|
Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 17
|
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
|
|
Apr 14
|
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
|
|
Apr 14
|
Roche’s Columvi combo gains EC approval for DLBCL
|
|
Apr 14
|
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 14
|
Roche Diagnostics supports UK eye cancer AI initiative
|
|
Mar 14
|
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
|
|
Mar 13
|
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 13
|
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
|
|
Mar 12
|
Roche, Zealand sign deal: What it means for weight loss drug space
|
|
Mar 12
|
Novo Nordisk Is Falling. Competition Is a Killer.
|
|
Mar 12
|
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
|
|
Mar 12
|
Novo Nordisk, Starbucks shares slumping: Trending Tickers
|
|
Mar 12
|
iRobot, Target, Novo Nordisk vs. Roche: Market Minute
|
|
Mar 12
|
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
|
|
Mar 12
|
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
|
|
Mar 12
|
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
|
|
Mar 12
|
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
|